ArticleCureus2026
Concomitant Diagnosis of Acute Promyelocytic Leukemia and Type 2 Diabetes Mellitus in a Child: Report of a Rare Case.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by the PML-RARA fusion gene and a high risk of coagulopathy. Type 2 diabetes mellitus (T2DM) is increasingly diagnosed in children and adolescents. To our knowledge, the concomitant diagnosis of these two conditions in the pediatric population has not been previously reported. We report the case of a 10-year-old girl presenting with fatigue, abdominal pain, and fever. Laboratory investigations revealed severe thrombocytopenia, leukocytosis, and 63% circulating blasts on peripheral blood smear. Bone marrow aspiration, immunophenotyping, and molecular analysis confirmed APL through detection of the t(15;17)(q24.1;q21.2) translocation and PML-RARA fusion gene. Based on a white blood cell count of 16.9 × 10⁹/L and a platelet count of 10 × 10⁹/L, the patient was classified as high-risk APL according to the Sanz classification. Severe disseminated intravascular coagulation was present at diagnosis. Concurrent metabolic evaluation demonstrated marked hyperglycemia, elevated HbA1c (8.1%), hyperinsulinemia, atherogenic dyslipidemia, and negative pancreatic autoantibodies, supporting a concomitant diagnosis of T2DM in the setting of overweight status, acanthosis nigricans, and a positive family history. Treatment was initiated according to the AML-MA 2011 induction protocol, comprising cytarabine and daunorubicin combined with all-trans retinoic acid (ATRA), intensive transfusion support, and a basal-bolus insulin regimen. At 18 months of follow-up, the patient remained in complete hematological remission under joint hematological and endocrinological surveillance. This case highlights the importance of considering metabolic disorders in children with hematologic malignancies who present with risk factors for insulin resistance. Emerging evidence suggests potential biological links between metabolic dysregulation and hematological malignancies. Early multidisciplinary management enabled successful control of both conditions and a favorable clinical outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.